AstraZeneca, a leading global biopharmaceutical company, has identified the drug localization project in Kazakhstan as a key focus of its operations. This was announced by Maria Shipuleva, the Country Director of AstraZeneca in Kazakhstan, at the Kazakhstan Pharmaceutical Forum held in Almaty on February 7. The Kazakh Health Ministry had previously inked a roadmap for the drug localization project in collaboration with several of the world’s largest companies, including AstraZeneca.
Shipuleva put forth several amendments designed to stimulate the growth of localized production and enhance its appeal to foreign investors. The main recommendations encompassed safeguarding investors’ intellectual property rights via data exclusivity regulations for preclinical and clinical trials and limiting the entry of counterfeit products into government procurement.
The proposal underscored the possibility of offsetting expenses during technology transfer and entering into an initial agreement with SK-Pharmacy for the acquisition of imported drugs that are subject to localization.
The forum, which saw the participation of representatives from the Kazakh Health Ministry, executives of top pharmaceutical companies, and industry experts, deliberated on proposals to expedite access to innovative drugs for patients in Kazakhstan.
About AstraZeneca
Headquartered in Cambridge, United Kingdom, AstraZeneca is an innovative global biopharmaceutical company that excels in the research, development, and commercialization of prescription medicines across a variety of therapeutic areas. With operations in over 100 countries, AstraZeneca’s innovative medicines are utilized by mn of patients globally.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)